This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Sarepta's Eteplirsen Boys Keep On Walking

Stocks in this article: SRPT GSK

CAMBRIDGE, Mass. ( TheStreet) -- Sarepta Therapeutics (SRPT - Get Report) issued a boring, 74-week update from its mid-stage study of eteplirsen in boys with Duchenne muscular dystrophy. The boys in the study basically walked just as well as they did when measured at 62 weeks and no new adverse events were reported.

Boring, in this case, is very good news and will help Sarepta as it seeks U.S. approval of eteplirsen as quickly as possible.

After 74 weeks, the six boys treated with eteplirsen were able to walk, on average, 2.2 meters less over six minutes than they walked at the beginning of the study. By comparison, when the boys performed the same walking test after 62 weeks, their walking ability dropped by 4.2 meters.

"We are encouraged to see a continued stabilization of walking ability in patients treated with eteplirsen for nearly one and a half years," said Sarepta CEO Chris Garabedian, in a statement. "These data are particularly compelling when viewed in the context of published natural history studies, which showed substantial declines on the 6-minute walk test over this timeframe in a similar ambulatory DMD population.

"Stable" is also the operative word for the four DMD boys who began the study on a placebo and were switched over to eteplirsen after 24 weeks. On the same six-minute walk test conducted after 74 weeks, these four boys walked 64.6 meters less, on average, than they did when the study began. When the same test was performed at 62 weeks, the decrease in walking distance was 63.8 meters.

Like the boys treated with eteplirsen from the beginning of the study, the four boys in the "control" arm demonstrated stable walking ability from 62 weeks through 74 weeks.

The safety of eteplirsen continues to look promising with no new adverse events reported in the 74-week update. No patients were hospitalized or required treatment discontinuation, which sets eteplirsen apart from the safety questions raised about a competing DMD drug from GlaxoSmithKline.

Sarepta met with officials from the U.S. Food and Drug Administration late last month seeking permission to file an accelerated approval application for eteplirsen based on data from the small phase II study. Sarepta is expected to announce the outcome of this meeting later in April.

Sarepta shares opened Friday trading up 28 cents to $34.71.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs